Literature DB >> 30385058

Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis.

Jad Shedrawy1, Martin Henriksson2, Maria-Pia Hergens3, H Helena Askling4.   

Abstract

BACKGROUND: The number of notified cases of Tick-Borne Encephalitis (TBE) in Sweden has been increasing the past years despite the increased use of TBE-vaccine not subsidized by the healthcare system. Stockholm County is a high endemic area and an earlier study has shown that low-income households have lower vaccination coverage even when they are at high risk. This paper aims to determine the cost-effectiveness of a publicly funded TBE vaccination program in Stockholm.
METHODS: In three different cohorts with individuals aged 3, 40 or 50 years, long-term costs and health outcomes of an out-of-pocket strategy (53% of the cohort is vaccinated on their own expenses) and a structured vaccination program (full cohort is vaccinated covered by the publicly funded health care system), were estimated using a Markov model. The Markov model predicts the costs and effects in term of Quality-adjusted Life Years (QALYs) over a lifetime horizon using a third-party healthcare payer perspective. The primary results are presented as an incremental cost effectiveness ratio (ICER) indicating the additional cost required to achieve one additional QALY with the structured vaccination program.
RESULTS: The results show that the structured vaccination program is associated with a gain in QALYs and increased costs compared with an out-of-pocket strategy. The calculated ICERs were 27 761, 99 527 and 160 827 SEK/QALY in cohorts of age 3, 40 and 50, respectively. The sensitivity analyses showed that the results are robust when varying different parameters.
CONCLUSION: Given the setting of Stockholm county, this analysis shows a cost per QALY of a free vaccinations program, especially for children of 3 years old, below generally acceptable cost-effectiveness thresholds in Sweden.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost-effectiveness; Costing; Policy; Sweden; TBE

Mesh:

Substances:

Year:  2018        PMID: 30385058     DOI: 10.1016/j.vaccine.2018.10.086

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Vaccination against Tick-Borne Encephalitis (TBE) in Italy: Still a Long Way to Go.

Authors:  Donatella Panatto; Alexander Domnich; Daniela Amicizia; Paolo Reggio; Raffaella Iantomasi
Journal:  Microorganisms       Date:  2022-02-18

Review 2.  Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives.

Authors:  Angelika Wagner; Birgit Weinberger
Journal:  Front Immunol       Date:  2020-04-23       Impact factor: 7.561

3.  Burden of Tick-Borne Encephalitis, Sweden.

Authors:  Daniel Slunge; Anders Boman; Marie Studahl
Journal:  Emerg Infect Dis       Date:  2022-02       Impact factor: 6.883

4.  A sociotechnical approach to vaccine manufacturer selection as part of a global immunization strategy against epidemics and pandemics.

Authors:  Fernando A F Ferreira; Devika Kannan; Ieva Meidutė-Kavaliauskienė; Inês M T Vale
Journal:  Ann Oper Res       Date:  2022-01-15       Impact factor: 4.854

5.  Predators in northern Germany are reservoirs for parasites of One Health concern.

Authors:  Patrick Waindok; Katharina Raue; Miguel L Grilo; Ursula Siebert; Christina Strube
Journal:  Parasitol Res       Date:  2021-02-06       Impact factor: 2.289

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.